Identification of New Drug Targets and Resistance Mechanisms in Mycobacterium tuberculosis
View/ Open
Author
Ioerger, Thomas R.
O’Malley, Theresa
Liao, Reiling
Guinn, Kristine M.
Hickey, Mark J.
Mohaideen, Nilofar
Murphy, Kenan C.
Boshoff, Helena I. M.
Mizrahi, Valerie
Sassetti, Christopher M.
Barry, Clifton E.
Sherman, David R.
Parish, Tanya
Sacchettini, James C.
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1371/journal.pone.0075245Metadata
Show full item recordCitation
Ioerger, T. R., T. O’Malley, R. Liao, K. M. Guinn, M. J. Hickey, N. Mohaideen, K. C. Murphy, et al. 2013. “Identification of New Drug Targets and Resistance Mechanisms in Mycobacterium tuberculosis.” PLoS ONE 8 (9): e75245. doi:10.1371/journal.pone.0075245. http://dx.doi.org/10.1371/journal.pone.0075245.Abstract
Identification of new drug targets is vital for the advancement of drug discovery against Mycobacterium tuberculosis, especially given the increase of resistance worldwide to first- and second-line drugs. Because traditional target-based screening has largely proven unsuccessful for antibiotic discovery, we have developed a scalable platform for target identification in M. tuberculosis that is based on whole-cell screening, coupled with whole-genome sequencing of resistant mutants and recombineering to confirm. The method yields targets paired with whole-cell active compounds, which can serve as novel scaffolds for drug development, molecular tools for validation, and/or as ligands for co-crystallization. It may also reveal other information about mechanisms of action, such as activation or efflux. Using this method, we identified resistance-linked genes for eight compounds with anti-tubercular activity. Four of the genes have previously been shown to be essential: AspS, aspartyl-tRNA synthetase, Pks13, a polyketide synthase involved in mycolic acid biosynthesis, MmpL3, a membrane transporter, and EccB3, a component of the ESX-3 type VII secretion system. AspS and Pks13 represent novel targets in protein translation and cell-wall biosynthesis. Both MmpL3 and EccB3 are involved in membrane transport. Pks13, AspS, and EccB3 represent novel candidates not targeted by existing TB drugs, and the availability of whole-cell active inhibitors greatly increases their potential for drug discovery.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3781026/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:11878840
Collections
- HMS Scholarly Articles [17917]
- SPH Scholarly Articles [6362]
Contact administrator regarding this item (to report mistakes or request changes)